2007 Chapter Meeting Presentations 2006 Chapter Meeting Presentations Type-2 Diabetes Mellitus - Learn more about Type-2 Diabetes Mellitus since long-term complications of diabetes include CVD. In fact, two out of three people with diabetes die from CVD. 2007 Chapter Meeting Presentations: Presentations from the Annual Chapter Meeting held October 12-14, 2007. All files are in a MS PowerPoint Show (.PPS) format. You do not need to have MS PowerPoint Installed on your computer to view the files. Each link opens a new window. Transforming Science into Quality Care by Alfred A. Bove, MD, PhD Treat Everyone to an LDL-C or 70mg/dl? by Daniel Edmundowicz MS, MD, FACC Reimbursement Challenges and Solutions for Cardiovascular Specialists by Kathleen Flood, Director, Payer Advocacy Gloom, Doom, and the Baby Boom: HealthCare in the Future by Raymond J. Gibbons, MD [ File 1 ] [ File 2 ] Negotiating Your Employment Contract by Vasilios J.Kalogredis, Esq. Treatment of Atrial Fibrillation: 2007 Update by David L. Scher, FACP, FACC, FHRS Achieving Accreditation in Echo, Nuclear and Vascular by Robert Skotnicki DO, FACC LDL: Lower IS Better by Andrew R. Waxler, MD, FACC Task Force on Performance Assessment, Recognition, Reinforcement and Reward (PAR3) by Janet Wright MD, FACC 2006 Chapter Meeting Presentations: Presentations from the 2006 Annual Chapter Meeting, held Friday, April 28, 2006 at the Wyndham Harrisburg-Hershey in Harrisburg, PA: CCA Practice Models Billing for Nurse Practitioner Services Michelle Ashby, CRNP and Paul Casale, MD, FACC Cardiac CT and CT Angiography: Techniques and Clinical Applications Ethan J. Halpern, MD Innovative Surgical Techniques Walter Pae, Jr., MD, FACC, FACS ACC Goals & Initiatives Including Imaging Gerald V. Naccarelli, MD, FACC Nuclear Imaging Bindukumar C. Kansupada, MD, FACC, MBA Type-2 Diabetes Mellitus: T2DM Drivers Driver One Reducing blood glucose and HbA1c levels reduces the risk of diabetic complications. Intensive therapy has been shown to be superior to conventional therapy in terms of reducing glycemia and diabetic complications. Driver Two When monotherapy with an oral agent is no longer adequate, combination therapy with two or more oral agents has been shown to significantly improve glycemic control. Driver Three When oral monotherapy or combination oral therapy is no longer adequate, insulin can be added to the regimen to significantly improve glycemic control. Driver Four Benefits of insulin therapy, such as improved outcomes and glycemic control, outweigh risks such as the potential for inducing hypoglycemia. Driver Five Type 2 diabetes mellitus is a disease consisting of two components: insulin resistance and insulin deficiency. Read the full diabetes module for cardiology. This Scientific Evidence Based Medicine Module was funded by an educational grant from Sanofi-Aventis Pharmaceuticals Education Center.